Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary

Molecular Brain Research

Volumn 55, Issue 2, 1998, Pages 285-292

  Inoue, Atsuko ^a   Seto, Mayumi ^a   Sugita, Sayori ^a   Hide, Izumi ^a   Hirose, Tsuyoshi ^b   Koga, Nobuyuki ^b   Kikuchi, Tetsuro ^b   Nakata, Yoshihiro ^a  

^a Inst Pharmaceutical Sci H   (Japan)

^b Tokushima Research Institute   (Japan)

Author keywords

3H Spiperone binding; Aripiprazole; Dopamine receptor; Haloperidol; Rat pituitary; RNase protection assay

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; PROLACTIN; SULPIRIDE; MESSENGER RNA; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; RIBONUCLEASE; SPIPERONE;

ANIMAL TISSUE; ARTICLE; GENE EXPRESSION; HYPOPHYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BIOSYNTHESIS; CELL MEMBRANE; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; CELL MEMBRANE; GENE EXPRESSION REGULATION; HALOPERIDOL; MALE; PIPERAZINES; PITUITARY GLAND; PROLACTIN; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; RIBONUCLEASES; RNA, MESSENGER; SPIPERONE;

EID: 0032052732     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(98)00009-6     Document Type: Article

References (35)

1. 2 receptor mRNA isoforms under haloperidol treatment, as evidenced by in situ hybridization in rat anterior pituitary. Neurosci. Lett. 130:1991;12-16.
2. 2-receptor messenger RNA is differentially regulated by dopaminergic agents in rat anterior and neurointermediate pituitary. Mol. Cell. Endocrinol. 67:1989;101-105.
3. Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocr. Rev. 6:1985;564-589.
4. Bunker M.T., Marken P.A., Schneiderhan M.E., Ruehter V.L. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J. Child Adolesc. Psychopharmacol. 7:1997;65-69.
5. 2 dopamine receptor cDNA. Nature. 336:1988;783-787.
6. 2 dopamine receptor in rat and bovine caudate nucleus. Nature. 343:1990;266-269.
7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
8. 2 dopamine receptor gene expression among individual melanotropes in the rat pituitary intermediate lobe. Mol. Cell. Neurosci. 5:1994;35-45.
9. Cooke N.E., Coit D., Weiner R.I., Baxter J.D., Martial J.A. Structure of cloned DNA complementary to rat prolactin messenger RNA. J. Biol. Chem. 255:1980;6502-6510.
10. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr. Res. 4:1991;121-156.
11. 2 dopamine receptor isoforms. Nature. 342:1989;923-926.
12. Gordreau J.L., Lookingland K.J., Moore K.E. 5-Hydroxytryptamine-2 receptor-mediated regulation of periventricular-hypophysial dopaminergic neuronal activity and the secretion of α-melanocyte-stimulating hormone. J. Pharmacol. Exp. Ther. 268:1994;175-179.
13. 2 dopamine receptor protein independent of RNA levels in mice. Soc. Neurosci. Abstr. 16:1990;1293.
14. 2 and Gi protein in the striatum of hemi-dopaminergic lesioned rats. Neurosci. Lett. 175:1994;107-110.
15. 2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 321:1997;105-111.
16. Inoue T., Domae M., Yamada K., Furukawa T. Effects of the novel antipsychotic agent 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277:1996;137-143.
17. Jaber M., Tison F., Fournier M.C., Bloch B. Differential influence of haloperidol and sulpiride on dopamine receptors and peptide mRNA levels in the rat striatum and pituitary. Mol. Brain Res. 23:1994;14-20.
18. 2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274:1995;329-336.
19. Levinson D.F. Pharmacologic treatment of schizophrenia. Clin. Ther. 13:1991;326-352.
20. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
21. Maurer R.A. Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Nature. 294:1981;94-97.
22. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
23. 2 dopamine receptors produced by alternative RNA splicing. Nature. 342:1989;296-299.
24. O'Dowd B.F. Structures of dopamine receptors. J. Neurochem. 60:1993;804-816.
25. Psinetti G.M., Osterburg H.H., Kelly A.B., Kohama S., Morgan D.G., Reinhard J.F., Stellwagen R.H., Finch C.E. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. Mol. Brain Res. 13:1992;63-67.
26. 2 receptor as revealed by the polymerase chain reaction. REBS Lett. 263:1990;18-22.
27. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
28. Sibley D.R., Monsma F.J. Jr. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:1992;61-69.
29. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
30. Strange P.G. New insights into dopamine receptors in the central nervous system. Neurochem. Int. 22:1993;223-236.
31. Toru M., Miura S., Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology. 10:1994;122S.
32. 2 subtype, uncoupled with adenylyl cyclase, inhibiting prolactin release from rat pituitary cells. J. Neurochem. 62:1994;1260-1266.
33. 4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiol. Aging. 15:1994;713-719.
34. Van der Kar L.D. Neuroendocrine pharmacology of serotonergic (5HT) neurons. Annu. Rev. Pharmacol. Toxicol. 31:1991;289-320.
35. 3H-SCH23390-binding in rat striatum: effects of lesions. Pharm. Res. 7:1990;280-282.